Small Molecules in Hematology
This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL...
Uloženo v:
| Médium: | Elektronický zdroj E-kniha |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
Cham :
Springer International Publishing,
2018.
|
| Vydání: | 3rd ed. 2018. |
| Edice: | Recent Results in Cancer Research,
212 |
| Témata: | |
| ISBN: | 9783319914398 |
| ISSN: | 0080-0015 ; |
| On-line přístup: |
|
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 003 | SK-BrCVT | ||
| 005 | 20220618102820.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 180801s2018 gw | s |||| 0|eng d | ||
| 020 | |a 9783319914398 | ||
| 024 | 7 | |a 10.1007/978-3-319-91439-8 |2 doi | |
| 035 | |a CVTIDW14062 | ||
| 040 | |a Springer-Nature |b eng |c CVTISR |e AACR2 | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Small Molecules in Hematology |h [electronic resource] / |c edited by Uwe M. Martens. |
| 250 | |a 3rd ed. 2018. | ||
| 260 | 1 | |a Cham : |b Springer International Publishing, |c 2018. | |
| 300 | |a VIII, 294 p. 28 illus., 17 illus. in color. |b online resource. | ||
| 490 | 1 | |a Recent Results in Cancer Research, |x 0080-0015 ; |v 212 | |
| 500 | |a Medicine | ||
| 505 | 0 | |a Imatinib -- Dasatinib -- Nilotinib -- Bosutinib -- Ponatinib -- Ruxolitinib -- Ibrutinib -- Lenalidomide -- Pomalidomide -- Enasidenib -- Midostaurin -- Alectinib -- Osimertinib -- Venetoclax -- Idelaslisib -- Carfilzomib -- Acalabrutinib. | |
| 516 | |a text file PDF | ||
| 520 | |a This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title. . | ||
| 650 | 0 | |a Hematology. | |
| 650 | 0 | |a Oncology . | |
| 856 | 4 | 0 | |u http://hanproxy.cvtisr.sk/han/cvti-ebook-springer-eisbn-978-3-319-91439-8 |y Vzdialený prístup pre registrovaných používateľov |
| 910 | |b ZE11342 | ||
| 919 | |a 978-3-319-91439-8 | ||
| 974 | |a andrea.lebedova |f Elektronické zdroje | ||
| 992 | |a SUD | ||
| 999 | |c 242690 |d 242690 | ||